Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (188) 188
multiple sclerosis (183) 183
index medicus (149) 149
clinical neurology (134) 134
female (111) 111
neurosciences (103) 103
male (99) 99
adult (84) 84
middle aged (77) 77
neurology (76) 76
immunology (48) 48
psychiatry (45) 45
medicine & public health (44) 44
animals (38) 38
research (36) 36
multiple sclerosis - drug therapy (35) 35
aged (31) 31
care and treatment (31) 31
neuroradiology (30) 30
multiple sclerosis - genetics (29) 29
multiple-sclerosis (28) 28
diagnosis (26) 26
pharmacology & pharmacy (26) 26
treatment outcome (26) 26
double-blind (25) 25
patients (25) 25
pathology (24) 24
diagnostic-criteria (23) 23
disease (22) 22
therapy (22) 22
young adult (22) 22
analysis (21) 21
disability (21) 21
inflammation (20) 20
cell biology (19) 19
health aspects (19) 19
immunologic factors - therapeutic use (19) 19
magnetic resonance imaging (19) 19
multiple sclerosis - complications (19) 19
adolescent (18) 18
depression (18) 18
genetic aspects (18) 18
interferon-beta - therapeutic use (18) 18
autoimmunity (17) 17
central-nervous-system (17) 17
gene expression (17) 17
multidisciplinary sciences (17) 17
multiple sclerosis - pathology (17) 17
multiple sclerosis - therapy (17) 17
spasticity (17) 17
apoptosis (16) 16
drug therapy (16) 16
fatigue (16) 16
genetics & heredity (16) 16
germany (16) 16
multiple sclerosis - immunology (16) 16
prevalence (16) 16
prognosis (16) 16
aged, 80 and over (15) 15
allergy and immunology (15) 15
development and progression (15) 15
disease progression (15) 15
experimental allergic encephalomyelitis (15) 15
experimental autoimmune encephalomyelitis (15) 15
prospective studies (15) 15
risk factors (15) 15
usage (15) 15
cancer (14) 14
immunohistochemistry (14) 14
interferon (14) 14
medical research (14) 14
multiple sclerosis - diagnosis (14) 14
quality of life (14) 14
retrospective studies (14) 14
cerebrospinal fluid (13) 13
glatiramer acetate (13) 13
interferon beta (13) 13
medicine (13) 13
medicine, experimental (13) 13
mice (13) 13
multiple sclerosis - physiopathology (13) 13
placebo-controlled trial (13) 13
rats (13) 13
risk (13) 13
antibodies (12) 12
association (12) 12
cohort studies (12) 12
disability evaluation (12) 12
expression (12) 12
genetic predisposition to disease (12) 12
genotype (12) 12
guidelines (12) 12
lymphocytes (12) 12
multiple sclerosis - psychology (12) 12
progressive multifocal leukoencephalopathy (12) 12
severity of illness index (12) 12
t-cells (12) 12
clinically isolated syndrome (11) 11
gene expression profiling (11) 11
genes (11) 11
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Unique characteristics of cold cathode carbon-nanotube-matrix field emitters
by Collins, Philip G and Collins, Philip G and Zettl, A and Zettl, A
Physical Review B - Condensed Matter and Materials Physics, ISSN 0163-1829, 04/1997, Volume 55, Issue 15, pp. 9391 - 9399
The attributes of electron field emission from disordered matrix arrays of carbon nanotubes are studied and found to be quite reproducible in spite of the... 
PHYSICS, CONDENSED MATTER | K UK PHYSICS, CONDENSED MATTER | ELECTRON-EMISSION | MICROTUBULES | COMPOSITE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Monoclonal antibodies in treatment of multiple sclerosis
by Rommer, P. S and Dudesek, A and Stüve, O and Zettl, U.K
Clinical & Experimental Immunology, ISSN 0009-9104, 03/2014, Volume 175, Issue 3, pp. 373 - 384
Summary Monoclonal antibodies (mAbs) are used as therapeutics in a number of disciplines in medicine, such as oncology, rheumatology, gastroenterology,... 
alemtuzumab | multiple sclerosis | daclizumab | natalizumab | rituximab | Daclizumab | Rituximab | Multiple sclerosis | Alemtuzumab | Natalizumab | CONTROLLED PHASE-3 TRIAL | IMMUNOLOGY | DISEASE-ACTIVITY | MULTICENTER TRIAL | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | NEUROMYELITIS-OPTICA | AUTOIMMUNE-DISEASES | GLATIRAMER ACETATE | PLACEBO-CONTROLLED TRIAL | LYMPHOCYTE DEPLETION | INTERFERON BETA-1A | Antibodies, Monoclonal - administration & dosage | Humans | Antibodies, Monoclonal - adverse effects | Immunologic Factors - administration & dosage | Antibodies, Monoclonal - therapeutic use | Immunologic Factors - adverse effects | Immunologic Factors - therapeutic use | Multiple Sclerosis - drug therapy | Monoclonal antibodies | Biological products | Drug therapy | Medical research | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Dysregulation of Inflammasome Priming and Activation by MicroRNAs in Human Immune-Mediated Diseases
by Boxberger, N and Hecker, M and Zettl, UK
JOURNAL OF IMMUNOLOGY, ISSN 0022-1767, 04/2019, Volume 202, Issue 8, pp. 2177 - 2187
Inflammasomes are protein complexes that respond to a wide range of pathogens and cellular damage signals. Their activation prompts the caspase-1-mediated... 
SYSTEMIC-LUPUS-ERYTHEMATOSUS | MULTIPLE-SCLEROSIS | GENETIC ASSOCIATION | PERIPHERAL-BLOOD | NLRP3 INFLAMMASOME | IMMUNOLOGY | NOD-LIKE RECEPTOR | BLOOD MONONUCLEAR-CELLS | DECREASED EXPRESSION | PARKINSONS-DISEASE | MIR-146A EXPRESSION
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Spasticity in multiple sclerosis: Contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions
by Patejdl, Robert and Zettl, Uwe K
Autoimmunity Reviews, ISSN 1568-9972, 09/2017, Volume 16, Issue 9, pp. 925 - 936
In contrast to other diseases that go along with spasticity (e.g. spinal cord injury), spasticity in chronic autoimmune diseases involving the CNS is... 
Spasticity | Neuroinflammation | Multiple sclerosis | Cytokines | Neurodegeneration | SYNAPTIC-TRANSMISSION | NECROSIS-FACTOR-ALPHA | IMMUNOLOGY | MECHANICAL-PROPERTIES | ENHANCED SPASTICITY | PARAVENTRICULAR NUCLEUS | MITOCHONDRIAL CHANGES | INTRATHECAL TRIAMCINOLONE-ACETONIDE | INTERFERON-BETA THERAPY | GLATIRAMER ACETATE | MS PATIENTS | Autoimmunity | Neurons | Health aspects | Immunotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients
by Fitzner, Brit and Hecker, Michael and Zettl, Uwe Klaus
Autoimmunity Reviews, ISSN 1568-9972, 2015, Volume 14, Issue 10, pp. 903 - 913
Abstract Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system, usually occurring in young adults and leading to... 
Allergy and Immunology | Multiple sclerosis | Molecular biomarker | Prognosis | Cerebrospinal fluid | Diagnosis | Monitoring | OLIGOCLONAL BANDS | CLINICALLY ISOLATED SYNDROME | AXONAL DAMAGE | NECROSIS-FACTOR-ALPHA | IMMUNOLOGY | SOLUBLE ADHESION MOLECULES | MYELIN OLIGODENDROCYTE GLYCOPROTEIN | INTRATHECAL IGM-SYNTHESIS | NEUROFILAMENT LIGHT | PROGNOSTIC MARKER | ANTIBODY-RESPONSE | Development and progression | Biological markers | Aquaporins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Animal models of multiple sclerosis—Potentials and limitations
by Mix, Eilhard and Meyer-Rienecker, Hans and Hartung, Hans-Peter and Zettl, Uwe K
Progress in Neurobiology, ISSN 0301-0082, 2010, Volume 92, Issue 3, pp. 386 - 404
▶ The classical MOG -EAE is complemented by novel cortical and toxic MS models. ▶ Putative autoantigens of EAE/MS include myelin and axonal glycoproteins and... 
Autoimmunity | Experimental autoimmune encephalomyelitis | Animal model | Immunogenetics | Multiple sclerosis | Immunomodulatory therapy | GLATIRAMER ACETATE TREATMENT | EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS | NEUROSCIENCES | MYELIN OLIGODENDROCYTE GLYCOPROTEIN | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | REGULATORY T-CELLS | BRAIN-BARRIER DISRUPTION | PHOSPHODIESTERASE INHIBITOR PENTOXIFYLLINE | CENTRAL-NERVOUS-SYSTEM | DISEASE-MODIFYING THERAPIES | Encephalomyelitis, Autoimmune, Experimental - physiopathology | History, 21st Century | Animals, Genetically Modified | History, 20th Century | Humans | Encephalomyelitis, Autoimmune, Experimental - immunology | Multiple Sclerosis - genetics | Clinical Trials as Topic | Gene Expression Profiling | Multiple Sclerosis - therapy | Encephalomyelitis, Autoimmune, Experimental - therapy | Multiple Sclerosis - physiopathology | Animals | Microarray Analysis | Multiple Sclerosis - immunology | History, 19th Century | Encephalomyelitis, Autoimmune, Experimental - genetics | Disease Models, Animal
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity
by Flachenecker, Peter and Henze, Thomas and Zettl, Uwe K
European Neurology, ISSN 0014-3022, 05/2014, Volume 71, Issue 5-6, pp. 271 - 279
Background: Nabiximols (Sativex®), a cannabinoid-based oromucosal spray, is an add-on therapy for patients with moderate to severe multiple sclerosis... 
Original Paper | Spasticity | Cannabinoids | Multiple sclerosis | Tolerability | Effectiveness | Nabiximols | CONTROLLED-TRIAL | RELIABILITY | ASHWORTH SCALE | NEUROSCIENCES | CLINICAL NEUROLOGY | EDSS | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Male | Neuromuscular Agents - therapeutic use | Muscle Spasticity - drug therapy | Young Adult | Multiple Sclerosis - physiopathology | Cannabidiol - adverse effects | Adult | Female | Surveys and Questionnaires | Cannabidiol - therapeutic use | Severity of Illness Index | Dronabinol - adverse effects | Treatment Outcome | Sleep - drug effects | Neuromuscular Agents - adverse effects | Aged | Muscle Spasticity - physiopathology | Plant Extracts - therapeutic use | Dronabinol - therapeutic use | Drug Combinations | Germany | Multiple Sclerosis - drug therapy | Plant Extracts - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Spasticity in patients with multiple sclerosis – clinical characteristics, treatment and quality of life
by Flachenecker, P and Henze, T and Zettl, U. K
Acta Neurologica Scandinavica, ISSN 0001-6314, 03/2014, Volume 129, Issue 3, pp. 154 - 162
Aims To gain real‐life data on demographic and clinical characteristics, treatment patterns, treatment satisfaction and quality‐of‐life of multiple... 
spasticity | quality‐of‐life | treatment satisfaction | multiple sclerosis | drug treatment | Spasticity | Multiple sclerosis | Quality-of-life | Treatment satisfaction | Drug treatment | DISABILITY | RELIABILITY | quality-of-life | SCALE | CLINICAL NEUROLOGY | Disability Evaluation | Multiple Sclerosis - psychology | Cross-Sectional Studies | Humans | Middle Aged | Male | Multiple Sclerosis - therapy | Activities of Daily Living | Multiple Sclerosis - complications | Muscle Spasticity - etiology | Quality of Life | Adult | Female | Surveys and Questionnaires | Retrospective Studies | Germany | Muscle Relaxants, Central - therapeutic use | Care and treatment | Age
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients
by Rommer, Paulus S and Zettl, Uwe K
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 03/2018, Volume 19, Issue 5, pp. 483 - 498
Introduction: Multiple sclerosis (MS) is an immune-mediated and neurodegenerative disease with an unpredictable outcome. Immune-modulatory treatment aims at... 
interferon beta | Multiple sclerosis | ocrelizumab | dimethylfumarate | alemtuzumab | cladribine | fingolimod | teriflunomide | glatiramer acetate | natalizumab | daclizumab | HIGH-YIELD PROCESS | CONTROLLED PHASE-3 | GRANULE CELL NEURONOPATHY | FUMARIC-ACID ESTERS | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | VARICELLA-ZOSTER-VIRUS | INTERFERON-BETA THERAPY | TERM-FOLLOW-UP | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL | DISEASE-MODIFYING THERAPIES | Alemtuzumab - adverse effects | Neoplasms - etiology | Crotonates - metabolism | Alemtuzumab - metabolism | Humans | Immunosuppressive Agents - therapeutic use | Natalizumab - adverse effects | Natalizumab - metabolism | Interferon-beta - therapeutic use | Interferon-beta - adverse effects | Natalizumab - therapeutic use | Fingolimod Hydrochloride - adverse effects | Fingolimod Hydrochloride - therapeutic use | Toluidines - therapeutic use | Toluidines - metabolism | Toluidines - adverse effects | Fingolimod Hydrochloride - metabolism | Crotonates - therapeutic use | Glatiramer Acetate - adverse effects | Cladribine - metabolism | Interferon-beta - metabolism | Cladribine - therapeutic use | Glatiramer Acetate - therapeutic use | Multiple Sclerosis - pathology | Glatiramer Acetate - metabolism | Immunosuppressive Agents - adverse effects | Immunologic Factors - adverse effects | Cladribine - adverse effects | Crotonates - adverse effects | Alemtuzumab - therapeutic use | Immunologic Factors - therapeutic use | Multiple Sclerosis - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Hans Queckenstedt (1876–1918)
by Kumbier, Ekkehardt and Zettl, Uwe K
Journal of Neurology, ISSN 0340-5354, 05/2017, Volume 264, Issue 5, pp. 1032 - 1034
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00415-016-8315-9 
CLINICAL NEUROLOGY | Neurology - history | History, 19th Century | Neurophysiology - history | History, 20th Century | Humans | Germany
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights